Douglas Pearce is a Cardiology physician affiliated with University of Tennessee Health Science Center. OpenAlex indexes 14 publications with 733 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4230 Harding Rd
Suite 330
Nashville, TN 372052013
Telephone
615-269-4545Registry record last updated 1 Dec 2017.
Clinical trials
- RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain
Sponsor: Saint Thomas Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20241 payment
- Merck Sharp & Dohme CorporationProgram year20214 payments
- Amarin Pharma Inc.Program year20213 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
84.7%Statin20.8%Atorvastatin Calcium50%Rosuvastatin Calcium32%Pravastatin Sodium11%Simvastatin7%Part D<11 patientsBeta blocker19.2%Metoprolol Succinate40%Carvedilol20%Bisoprolol-Hydrochlorothiazide20%Metoprolol Tartrate13%Bisoprolol Fumarate7%Part D<11 patients+ 12 more classes in this area
Blood & clotting
10.2%Factor Xa inhibitor5.8%Eliquis75%Xarelto25%Part D<11 patientsP2Y12 inhibitor4.4%Clopidogrel100%Part D≥22 patientsMetabolism & gastrointestinal
5.1%Potassium supplement2%Potassium Chloride100%Part D<11 patientsSGLT2 inhibitor1.8%Farxiga100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Csaba Kovesdy, MD
University of Tennessee Health Science Center
David Shibata, MD
University of Tennessee Health Science Center
Helmut Steinberg, MD
University of Tennessee Health Science Center
Adam Arthur, MD
University of Tennessee Health Science Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”